The shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of a Restricted Stock Unit Award granted March 17, 2021.

The shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of a Restricted Stock Unit Award granted March 2, 2022.

The shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of a Restricted Stock Unit Award granted April 26, 2022.

The shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of a Restricted Stock Unit Award granted April 24, 2023.

The shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of a Restricted Stock Award granted April 23, 2024.

The shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of a Restricted Stock Award granted April 15, 2025.

/s/ Kelli Faerber, Attorney-In-Fact for Samantha Jacobson


Amount includes 3,707 of unvested Restricted Stock Units.

/s/ Jacob J. Guild, Attorney-in-Fact for Heidi E. Rogers


The shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of a Restricted Stock Award granted April 26, 2022.

The shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of a Restricted Stock Award granted April 24, 2023.

/s/ Kelli Faerber, Attorney-in-Fact for Jay R. Grant


Common Stock

Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. 25,134 of the RSUs granted on August 15, 2025 will vest on August 15, 2026, 25,133 will vest on August 15, 2027, and 25,134 will vest on August 15, 2028.

Chief Administrative and Transformation Officer

/s/ Kevin Macikowski, by power of attorney


These shares were withheld by the Company in order to satisfy the Reporting Person's tax liability incident to a vesting of restricted stock.

/s/ Sean N. Markowitz under POA by Lorraine Mitchelmore


The shares were withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of a Restricted Stock Award granted June 1, 2023.

/s/ Kelli Faerber, Attorney-in-Fact for Laura Schenkein


The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.

The sales were executed in multiple trades at prices ranging from $5.02 to $5.35. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

/s/ William Iwaschuk, Attorney-in-Fact for Patrick Arthur Kelly


Bernal Maya

C/O AST SPACEMOBILE, INC., MIDLAND AIR &

Represents a payment of tax liability by withholding securities incident to the vesting of Restricted Stock Units representing 7,415 shares of Class A Common Stock issued in accordance with Rule 16b-3, resulting in a net vested number of 4,919 shares.


Common Stock

These restricted stock units vest in four equal annual installments beginning on August 17, 2024, and upon vesting, will each be settled by delivery of one share of common stock, an equivalent amount of cash, or a combination thereof.

Represents shares withheld to pay taxes applicable to vesting of restricted stock units.

Title: Senior Vice President and Chief Information Officer


Represents a transfer of shares from the Reporting Person to a trust held by the Reporting Person.

Represents securities held by the Jeff Green Trust (the "Trust"). Mr. Green is a Trustee of the Trust and has investment and voting control over the shares held by the Trust, and may be deemed to indirectly beneficially own the shares held by the Trust.

Represents securities held by the Jeff T. Green Family Foundation (the "Foundation"). Mr. Green is the sole member and director of the Foundation and has investment and voting control over the shares held by the Foundation, and may be deemed to indirectly beneficially own the shares held by the Foundation.

/s/ Kelli Faerber, Attorney-in-Fact for Jeffrey Terry Green


The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.06 to $25.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

/s/ Jennifer J. Rhodes, Attorney-in-Fact


Mize Gary W.

C/O GEVO, INC. 345 INVERNESS DRIVE SOUTH

Common Stock

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.67 to $1.76 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.


Common Stock

Common Stock

Each restricted stock unit represents a contingent right to receive one share of HLIT common stock.


Represents achievement of 125% of the 75,000 target number of performance-based stock unit awards ("PSUs") granted on August 15, 2024, following certification by the Issuer's compensation committee that the applicable company and individual performance conditions had been satisfied. One third of the PSUs representing 31,250 shares of Class A Common Stock vested immediately on August 15, 2025 and the remaining PSUs will vest equally on August 15, 2026 and August 15, 2027, subject to the Reporting Person's continued service through the vesting dates. Each PSU represents a contingent right to receive one share of the Issuer's Class A Common Stock.

Represents a payment of tax liability by withholding securities incident to the vesting of PSUs representing 31,250 shares of Class A Common Stock issued in accordance with Rule 16b-3, resulting in a net vested number of 18,953 shares.

Represents a payment of tax liability by withholding securities incident to the vesting of Restricted Stock Units representing 25,000 shares of Class A Common Stock issued in accordance with Rule 16b-3, resulting in a net vested number of 15,162 shares.


Common Stock

Common Stock


Subscription of shares was dated August 1, 2025, with NAV per share pricing as of August 1, 2025, which was finalized on August 19, 2025.

Shares are held by Daren and Louise Shaw Trust, of which Mr. Daren Shaw is one of the trustees and beneficiaries.


Includes 74 shares acquired under the Alaska Air Group, Inc. Employee Stock Purchase Plan on April 30, 2025, in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

/s/ Howard Kuppler, by power of attorney


Sale made by the reporting person pursuant to company policy limiting transactions to designated open trading period.


Held by 2023 Grantor Retained Annuity Trust

Held by 2025 Grantor Retained Annuity Trust#2

Common Stock

Common Stock

Includes a total of 60,964 restricted stock units that have not yet vested.

The price reported is the weighted average price. The shares were sold in multiple transactions at prices ranging from $59.00 to $59.175, inclusive. The reporting person undertakes to provide to the SEC, the issuer and any security holder full information regarding the number of shares and the prices at which the shares were sold.

The price reported is the weighted average price. The shares were sold in multiple transactions at prices ranging from $58.716 to $58.73, inclusive. The reporting person undertakes to provide to the SEC, the issuer and any security holder full information regarding the number of shares and the prices at which the shares were sold.

The number of shares reported reflects the transfer of 83,486 shares to the 2025 Grantor Annuity Trust #2 on August 19, 2025, for which Mr. Fink serves as Trustee, such transfer being exempt under Rule 16b-13.

/s/ Angela M. Pla, Attorney-in-Fact for Nicholas I. Fink


Common Stock

The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 29, 2024.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.725 to $63.625. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.83 to $63.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

These shares are held by 2008 D&T Girouard Revocable Trust, for which the Reporting Person serves as Trustee.

These shares are held by David J Girouard, as trustee of the DTG GRAT LLC, dated May 23,2023.

These shares are held by Tristen Baird Willard, as trustee of the TMG 2020 EXEMPT GIFT TRUST, dated October 19, 2020.

These shares are held by Tristen Baird Willard, as trustee of the JRG 2020 EXEMPT GIFT TRUST, dated October 19, 2020.

These shares are held by Tristen Baird Willard, as trustee of the TMG 2020 NONEXEMPT GIFT TRUST, dated October 19, 2020

These shares are held by Tristen Baird Willard, as trustee of the JRG 2020 NONEXEMPT GIFT TRUST, dated October 19, 2020.

All of the shares subject to this option are fully vested and exercisable as of the date hereof.


The sale being reported on this Form 4 is the sale of Chess Depositary Interests ("CDIs") as converted on a 1:3 common stock to CDI ratio. The CDIs were traded on the Australian Securities Exchange (the "ASX") and were held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX.

Reflects the number of common stock equivalent shares underlying the CDIs sold on the ASX.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.91 to $84.85, inclusive, per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3.

Reflects the weighted average sale price of the CDIs sold, as converted to USD by multiplying the amount by 3, based on the 3:1 conversion ratio for CDIs to common stock, and then multiplying by the exchange rate of 0.6505 in effect at the time of the sale as published by the Reserve Bank of Australia.

Includes the number of common stock underlying CDIs as converted on a 1:3 common stock to CDI ratio. The CDIs are traded on the ASX and are held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX.

Includes  2,810  restricted stock units previously granted, each of which represents a contingent right to receive one share of the Issuer's common stock upon vesting.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.36 to $86.22, inclusive, per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 7.

Reflects the weighted average sale price of the CDIs sold, as converted to USD by multiplying the amount by 3, based on the 3:1 conversion ratio for CDIs to common stock, and then multiplying by the exchange rate of 0.652 in effect at the time of the sale as published by the Reserve Bank of Australia.

The Reporting Person has shared investment control over Carthona Capital FS Pty Ltd. ("Carthona Capital"). Carthona Capital is a member of ICCA Labs, LLC, an entity that holds an aggregate of 8,219 shares of the Issuer's common stock. The number of shares held as reported herein represents Carthona Capital's proportionate ownership interest in ICCA Labs, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.


The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.63  to $46.715, inclusive. The Reporting Person undertakes to provide Mercantile Bank Corporation, any security holder of Mercantile Bank Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.


Represents restricted stock units that vest in equal annual increments over the three-year period following the grant date.


Common Stock, $0.001 par value per share

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2024.

/s/ Richard Mattessich, Attorney-in-fact


Represents shares of the Issuer's Class A Common Stock withheld by the Issuer solely to satisfy tax withholding obligations in connection with the net issuance of shares of the Issuer's Class A Common Stock delivered to the reporting person on August 15, 2025, from the vesting of restricted stock units ("RSUs"), and does not represent a sale by the reporting person.

Includes 1,320,859 RSUs.

/s/ Elizabeth Fisher, as attorney in fact for Thomas Neergaard Hansen


Includes 883,657 RSUs.

/s/ Elizabeth Fisher, as attorney in fact for Andrew Casey


Includes 710,732 RSUs.

/s/ Elizabeth Fisher, as attorney in fact for Liu Curtis


Class A Common Stock

The sales reported were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on March 12, 2025.

This transaction was executed in multiple trades at prices ranging from $11.3800 to $11.5400. The price reported above reflects the weighted average sale price. The reporting person hereby
undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was
effected.

The option is early exercisable. 1/48th of the shares subject to the option vest on each monthly anniversary measured from December 10, 2020 (the"Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the VestingCommencement Date.

/s/ Elizabeth Fisher, as attorney in fact for Schultz Erica


43,945 shares of Class A Common Stock were withheld by the Company for the purposes of satisfying tax withholding obligations in connection with the vesting of 86,538 Restricted Stock Units on August 15, 2025.

The closing price of the Issuer's Class A Common Stock on August 14, 2025.


The shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs.

/s/ Lindsey Cochran, by power of attorney


Represents dividend equivalent units accrued on August 15, 2025 as dividends that were paid on the common shares underlying restricted stock units.  The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate.  Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock.


Class A Common Stock, par value $0.001 per share

This transaction was executed in multiple trades at prices ranging from $0.39 to $0.43 per share. The price reported above reflects the weighted average purchase price on the date indicated. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares.

This transaction was executed in multiple trades at prices ranging from $0.39 to $0.40 per share. The price reported above reflects the weighted average purchase price on the date indicated. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares.

This transaction was executed in multiple trades at prices ranging from $0.39 to $0.41 per share. The price reported above reflects the weighted average purchase price on the date indicated. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares.


28,183 shares of Class A Common Stock were withheld by the Company for the purposes of satisfying tax withholding obligations in connection with the vesting of 59,425 Restricted Stock Units on August 15, 2025.

The sale reported in this transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024, as described in the Issuer's Quarterly Report on Form 10-Q for the three months ended September 30, 2024, filed with the Securities and Exchange Commission on November 7, 2024.


Represents dividend equivalent units accrued on August 15, 2025 as dividends that were paid on the common shares underlying restricted stock units and deferred stock units previously granted to the Reporting Person under the Company's Long-Term Incentive Plans and Non-Employee Director Deferred Compensation Plan.  Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock.


Common Stock, Par Value $0.0001 Per Share

Each restricted stock unit ("RSU") and performance stock unit ("PSU") represents a contingent right to receive one share of the Issuer's common stock.

On July 17, 2025, the Reporting Person was granted 11,000 RSUs vesting in three nearly equal annual installments (33%,33%, 34%), beginning on August 7, 2026.

On July 17, 2025, the Reporting Person was granted 5,500 PSUs, a portion of which vests, if the volume-weighted average price of the Issuer's common stock for any consecutive sixty (60) trading-day period equals or exceeds a stock price target.

On July 17, 2025, the Reporting Person was granted 5,500 stock options vesting in three nearly equal annual installments (33%,33%, 34%), beginning on August 7, 2026.


Mr. Guthrie is the Investment Manager of Guthrie 2012 Investments LP, which owns 34,106 shares of common stock. Mr. Guthrie disclaims beneficial ownership of the shares of common stock held by Guthrie 2012 Investments LP, except to the extent of his direct pecuniary interest therein.


33,614 shares of Class A Common Stock were withheld by the Company for the purposes of satisfying tax withholding obligations in connection with the vesting of 66,191 Restricted Stock Units on August 15, 2025.


This sale was executed pursuant to a Rule 10b5-1 Plan that was entered into by the Reporting Person during an open trading window and disclosed by the Issuer on Form 8-K on March 28, 2024.  This sale was executed in multiple trades ranging from $100.31  to $100.44, inclusive. The price reported above represents the weighted average purchase price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and prices at which the transaction was effected.


EVP, Chief Technology and Operating Officer


SVP, Chief Accounting Officer and Controller


Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the restricted stock units and does not represent a sale.

Includes restricted stock units.


Represents dividend equivalent units accrued on August 15, 2025 as dividends that were paid on the common shares underlying restricted stock units. The dividend equivalent units vest
proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate. Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock.


19,478 shares of Class A Common Stock were withheld by the Company for the purposes of satisfying tax withholding obligations in connection with the vesting of 54,445 Restricted Stock Units on August 15, 2025.

The closing price of the Issuer's Class A Common Stock on August 14, 2025.


The sales reported on this Form 4 were executed pursuant to a trading plan entered into by the reporting person on March 26, 2024 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

Includes shares of Class A Common Stock that have not yet vested.

/s/ Robin Schulman, Attorney-in-Fact for Karen Blasing


Shares withheld to cover tax obligations in connection with the vesting of Restricted Stock Units ("RSUs").

Includes previously reported RSUs.


Class A Common Stock

Each share of the Issuer's Class B common stock (the "Class B Stock") is convertible into one share of the Issuer's Class A common stock at any time and will convert automatically upon certain transfers and upon the earlier of (i) ten years from the date of the Issuer's initial public offering ("IPO"), (ii) the death or disability of the Reporting Person, (iii) the first date following the completion of the IPO on which the number of shares of outstanding Class B Stock (including shares of Class B Stock subject to outstanding stock options) is less than 5% of the aggregate number of shares of the Issuer's common stock then outstanding and (iv) the date specified by a vote of the holders of two-thirds of the then outstanding shares of Class B Stock.

These securities are held by the Sytse Sijbrandij Revocable Trust dated February 21, 2019, of which the Reporting Person is the sole trustee.

This transaction was executed pursuant to a trading plan entered into by the reporting person, as the sole trustee of the Sytse Sijbrandij Revocable Trust dated February 21, 2019, on December 26, 2024 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.83 to $44.80, inclusive. The Reporting Person undertakes to provide to GitLab Inc., any security holder of GitLab Inc., or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote 4, footnote 5, and footnote 6.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.87 to $45.86, inclusive.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.87 to $46.28, inclusive.

/s/ Robin Schulman, Attorney-in-Fact for Sytse Sijbrandij


Common Stock

The reported phantom stock units were acquired pursuant to a dividend reinvestment feature under the Synchrony Financial Deferred Compensation Plan (the "Deferred Compensation Plan") and are to be settled, in cash, six months following the Reporting Person's separation from service to the Company, subject to the requirements set forth in the Deferred Compensation Plan. Each phantom stock unit is the economic equivalent of one share of Synchrony Financial common stock.


Common Stock

Common Stock

Common Stock

Common Stock

The restricted stock units vested in full on August 15, 2025. Vested shares were delivered to the reporting person upon vest.

Each Performance Stock Unit (PSU) granted under the Microchip Technology Incorporated (Microchip) 2004 Equity Incentive Plan represents a contingent right to receive shares of Microchip common stock based on the relative total shareholder return (TSR) of Microchip common stock compared to a peer group of twenty companies over a three-year period ending on June 30, 2024. The target number of PSU shares that may be earned is reported in the table above, the minimum number of shares that may be earned is zero if Microchip's TSR is at or lower than the 25th percentile of the peer group and the maximum number of shares that may be earned is 200% of the target if Microchip's TSR is at or higher than the 75th percentile of the peer group. Earned PSUs will vest on August 15, 2025 as long as the reporting person remains a service provider through the vesting date. Vested shares were delivered to the reporting person upon vest.

The restricted stock units vest in four quarterly installments of 1,406 shares beginning November 15, 2023, one quarterly installment of 702 shares on November 15, 2024, one quarterly installment of 704 shares on February 15, 2025 and six quarterly installments of 702 shares beginning on May 15, 2025. Vested shares were delivered to the reporting person upon vest.

Each Performance Stock Unit (PSU) granted under the Microchip Technology Incorporated (Microchip) 2004 Equity Incentive Plan represents a contingent right to receive shares of Microchip common stock based on Microchip's cumulative non-GAAP operating margin over a period of 12 quarters ending September 30, 2024. The target number of PSU shares that may be earned is reported in the table above and is based on Microchip achieving a cumulative non-GAAP operating margin of 40.0% over the 12 quarter measurement period. The actual number of shares that may be earned can be higher or lower than the target depending on Microchip's non-GAAP operating margin over the measurement period. Earned PSUs vested ratably over eight quarters beginning on November 15, 2024 as long as the reporting person remains a service provider through the vesting date. Vested shares were delivered to the reporting person upon vest.


Includes previously reported RSUs.


Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Performance Stock Options (Right to Buy)

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Fully exercisable.

Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.

Options to purchase 11,305 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.

Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.

13,159 restricted stock units vest on 11/1/2025.

Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

4,010 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 4,011 restricted stock units vest on 8/15/2027.

Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028.

11,545 restricted stock units vest on each of 11/1/2025 and 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.

Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

4,903 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 4,904 restricted stock units vest on 8/15/2028.

Options to purchase 12,544 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.

/s/ Andrew Nick as Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed


Shares held Indirectly, by Trust and by Family Limited Partnership.

Common Stock

Common Stock

Of the 10,166,473 shares held, 4,260,601 shares were held by The Sanghi Trust; and 5,905,872 shares were held by The Sanghi Family Limited Partnership.

Of the 10,164,265 shares held, 4,258,393 shares were held by The Sanghi Trust; and 5,905,872 shares were held by The Sanghi Family Limited Partnership.

Of the 10,169,611 shares held, 4,263,739 shares were held by The Sanghi Trust; and 5,905,872 shares were held by The Sanghi Family Limited Partnership.

Of the 10,167,400 shares held, 4,261,528 shares were held by The Sanghi Trust; and 5,905,872 shares were held by The Sanghi Family Limited Partnership.

The restricted stock units vested in full on August 15, 2025. Vested shares were delivered to the reporting person upon vest.

Each Performance Stock Unit (PSU) granted under the Microchip Technology Incorporated (Microchip) 2004 Equity Incentive Plan represents a contingent right to receive shares of Microchip common stock based on the relative total shareholder return (TSR) of Microchip common stock compared to a peer group of twenty companies over a three-year period ending on June 30, 2024. The target number of PSU shares that may be earned is reported in the table above, the minimum number of shares that may be earned is zero if Microchip's TSR is at or lower than the 25th percentile of the peer group and the maximum number of shares that may be earned is 200% of the target if Microchip's TSR is at or higher than the 75th percentile of the peer group. Earned PSUs will vest on August 15, 2025 as long as the reporting person remains a service provider through the vesting date. Vested shares were delivered to the reporting person upon vest.


These shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 22, 2024.

The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $66.60 to $67.59 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $67.76 to $68.36 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.


Class A Common Stock

Includes previously reported Restricted Stock Units ("RSUs").

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2024.

This sale price represents the weighted average sale price of the shares sold ranging from $24.70 to $24.73 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Shares withheld to cover tax obligations in connection with the vesting of RSUs.

The shares subject to the option are fully vested and exercisable.


Represents dividend equivalent units accrued on August 15, 2025 as dividends that were paid on the common shares underlying restricted stock units and deferred stock units previously granted to the Reporting Person under the Company's Long-Term Incentive Plans and Non-Employee Director Deferred Compensation Plan.  Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock.


Common Stock

Each unit represents a contingent right to receive one share of Bank of America Corporation common stock.

Disposition of shares to the issuer to satisfy a tax withholding obligation.

On February 15, 2022, the reporting person was granted units, vesting in sixteen equal quarterly installments commencing May 15, 2022.


Common Stock

Common Stock

Common Stock

The restricted stock units vested in full on August 15, 2025.  Vested shares were delivered to the reporting person upon vest.

The restricted stock units vest in nine quarterly installments of 338 shares beginning November 15, 2023, and three quarterly installments of 340 shares beginning on February 15, 2026.  Vested shares were delivered to the reporting person upon vest.


Represents dividend equivalent units accrued on August 15, 2025 as dividends that were paid on the common shares underlying restricted stock units.  The dividend equivalent units vest proportionately with and are subject to settlement and expiration upon the same terms as the restricted stock units to which they relate.  Each dividend equivalent unit is the economic equivalent of one share of Synchrony Financial common stock.


Common Stock

Common Stock

Common Stock

Each Performance Stock Unit (PSU) granted under the Microchip Technology Incorporated (Microchip) 2004 Equity Incentive Plan represents a contingent right to receive shares of Microchip common stock based on the relative total shareholder return (TSR) of Microchip common stock compared to a peer group of twenty companies over a three-year period ending on June 30, 2024.  The target number of PSU shares that may be earned is reported in the table above, the minimum number of shares that may be earned is zero if Microchip's TSR is at or lower than the 25th percentile of the peer group and the maximum number of shares that may be earned is 200% of the target if Microchip's TSR is at or higher than the 75th percentile of the peer group.  Earned PSUs will vest on August 15, 2025 as long as the reporting person remains a service provider through the vesting date. Vested shares were delivered to the reporting person upon vest.

The restricted stock units vest in four quarterly installments of 868 shares beginning November 15, 2023, and eight quarterly installments of 870 shares beginning on November 15, 2024.  Vested shares were delivered to the reporting person upon vest.


Includes 10 shares acquired through dividend reinvestment plan as of June 30, 2025.

Marcelo L. Eduardo by Granville Tate, Jr., POA


Common Stock

Common Stock

Common Stock

Common Stock

The restricted stock units vested in full on August 15, 2025. Vested shares were delivered to the reporting person upon vest.

Each Performance Stock Unit (PSU) granted under the Microchip Technology Incorporated (Microchip) 2004 Equity Incentive Plan represents a contingent right to receive shares of Microchip common stock based on the relative total shareholder return (TSR) of Microchip common stock compared to a peer group of twenty companies over a three-year period ending on June 30, 2024. The target number of PSU shares that may be earned is reported in the table above, the minimum number of shares that may be earned is zero if Microchip's TSR is at or lower than the 25th percentile of the peer group and the maximum number of shares that may be earned is 200% of the target if Microchip's TSR is at or higher than the 75th percentile of the peer group. Earned PSUs will vest on August 15, 2025 as long as the reporting person remains a service provider through the vesting date. Vested shares were delivered to the reporting person upon vest.

The restricted stock units vest in three quarterly installments of 1,556 shares beginning November 15, 2023, one quarterly installment of 1,554 shares on August 15, 2024, and eight quarterly installments of 776 shares beginning on November 15, 2024. Vested shares were delivered to the reporting person upon vest.

Each Performance Stock Unit (PSU) granted under the Microchip Technology Incorporated (Microchip) 2004 Equity Incentive Plan represents a contingent right to receive shares of Microchip common stock based on Microchip's cumulative non-GAAP operating margin over a period of 12 quarters ending September 30, 2024. The target number of PSU shares that may be earned is reported in the table above and is based on Microchip achieving a cumulative non-GAAP operating margin of 40.0% over the 12 quarter measurement period.  The actual number of shares that may be earned can be higher or lower than the target depending on Microchip's non-GAAP operating margin over the measurement period. Earned PSUs will vest ratably over eight quarters beginning on November 15, 2024 as long as the reporting person remains a service provider through the vesting date. Vested shares were delivered to the reporting person upon vest.


Shares withheld to cover tax obligations in connection with the vesting of Restricted Stock Units ("RSUs") and Performance-based Restricted Stock Units ("PSUs").

Includes previously reported RSUs and PSUs.

Includes shares acquired by the Reporting Person pursuant to the Issuer's Employee Stock Purchase Plan.

This sale price represents the weighted average sale price of the shares sold ranging from $24.70 to $24.73 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.


BERKOWITZ BRUCE R

C/O FAIRHOLME CAPITAL MANAGEMENT, L.L.C.

The reported transactions were in securities held by The Fairholme Fund, a series of Fairholme Funds, Inc. (the "Fairholme Fund"). The securities may be deemed to be beneficially owned by Mr. Bruce R. Berkowitz ("Mr. Berkowitz") because he controls the sole member of Fairholme Capital Management, LLC ("Fairholme"), which may be deemed to have beneficial ownership of the securities because Fairholme serves as the investment manager to the Fairholme Fund. Mr. Berkowitz and Fairholme disclaim beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that Mr. Berkowitz and Fairholme are the beneficial owners of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.

The reported securities are directly owned by Mr. Berkowitz.


This transaction represents the automatic withholding of shares of the Issuer's common stock upon the vesting of restricted stock units in order to satisfy the Reporting Person's tax withholding obligations.

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 20, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.70 to $10.88, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

/s/ Michelle Sparks, Attorney-in-Fact for Noel Bertram Watson


Represents shares that have been withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of restricted stock units.

These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 11, 2025.


The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.

/s/ Michelle Sparks, Attorney-in-Fact for Jeffrey M. Stibel


Amount includes includes 2,803 of unvested Restricted Stock Units.


The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 1, 2025.

This transaction was executed in multiple trades at prices ranging from $53.7900 to $54.7800. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Total includes Restricted Stock Units.

/s/ Michael Brudoley as attorney-in-fact for Jeffrey Hurd


On August 18, 2025, the reporting person transferred 389 shares of Trustmark Corporation common stock to the named trust for no consideration.  The reporting person is the trustee or a co-trustee of the trust and members of his immediate family are the sole beneficiaries of the trust.  The reporting person remains the beneficial owner of the securities held by the trust.

Gerard R. Host by Granville Tate, Jr., POA


This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025.

/s/ Michelle Sparks, Attorney-in-Fact for Nicole Miller


Common Stock

The sales reported and options exercised on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2025.

Includes Restricted Stock Units.

This transaction was executed in multiple trades at prices ranging from $52.5650 to $53.5649 The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected.

This transaction was executed in multiple trades at prices ranging from $53.5650 to $53.6400. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was affected.

Grant of employee stock option under the Issuer's 2019 Omnibus Incentive Plan exempt under Rule 16b-3. The options vested in three installments beginning on February 26, 2021.

/s/ Michael Brudoley as attorney-in-fact for Mark Pearson


The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.82 to $10.98, inclusive. The reporting person undertakes to provide to The Joint Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.69 to $10.70, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.


Represents shares that have been withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of restricted stock units.


This transaction was executed in multiple trades at prices ranging from $31.10 to $31.26; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

This transaction was executed in multiple trades at prices ranging from $30.81 to $31.04; the price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

/s/ Martijn van Steenpaal, as Attorney-in-Fact for Randall C. Stuewe


The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2024.

The transaction was executed in multiple trades at prices ranging from $258.0800 to $259.0745. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.

The transaction was executed in multiple trades at prices ranging from $259.0808 to $259.5500. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.

The transaction was executed in multiple trades at prices ranging from $257.6300 to $258.6100. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.

The transaction was executed in multiple trades at prices ranging from $258.6500 to $258.9700. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.

The transaction was executed in multiple trades at prices ranging from $258.3250 to $259.2900. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.

The transaction was executed in multiple trades at prices ranging from $259.3400 to $260.3200. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.

The transaction was executed in multiple trades at prices ranging from $260.3450 to $261.0350. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, Morningstar or a shareholder of Morningstar full information regarding the number of shares and prices at which the transaction was effected.

The shares are held in grantor retained annuity trusts for the benefit of the reporting person and his children. The reporting person serves as trustee of the grantor retained annuity trusts.

The shares are held in trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts.

/s/ Kathleen Peacock, by power of attorney


These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 11, 2025.


Shares were withheld as payment of a tax liability incident to vesting of restricted stock units issued in accordance with Rule 16b-3.

Includes 3,536 shares held directly, 9,387 restricted stock unit, and 350 earned performance share units with additional service-based vesting.

William Zola, pursuant to power of attorney


Includes 15,726 shares which were granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 1,551 shares on each of August 20, 2025, and November 20, 2025, 1,554 shares on March 6, 2026, 1,246 shares on each of May 20, 2026, August 20, 2026, and November 20, 2026,1,252 shares on March 6, 2027, 1,012 shares on each of May 20, 2027, August 20, 2027, and November 20, 2027, 1,016 shares on March 6, 2028, 506 shares of each on May 20, 2028, August 20, 2028, and November 20, 2028, and 510 shares on March 6, 2029, if he is an employee of the Company on those dates.


Reflects the grant of restricted stock units by the Issuer to the Reporting Person on August 18, 2025. The restricted stock units are scheduled to vest in three equal installments on August 18, 2026, August 18, 2027 and August 18, 2028, subject to the Reporting Person's continued employment with the Issuer. Each restricted stock unit represents the right to receive one share of the Issuer's common stock.

Includes 125,000 restricted stock units scheduled to vest in three equal installments on August 18, 2026, August 18, 2027 and August 18, 2028, subject to the Reporting Person's continued employment with the Issuer. Each restricted stock unit represents the right to receive one share of the Issuer's common stock.


Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

This option vests on the earlier of the one-year anniversary of the grant date (2/3/2025) or the date of Bio-Techne's 2025 annual meeting of shareholders.

Fully vested.

Options to purchase 520 shares vest on each of 8/6/2022, 8/6/2023 and 8/6/2025; and options to purchase 516 shares vest on 8/6/2024.

Options to purchase 528 shares vest on 8/15/2023 and 8/15/2025; and options to purchase 524 shares vest on 8/15/2024 and 8/15/2026.

Options to purchase 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027.

Options to purchase 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.

Options to purchase 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029.

Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

119 restricted stock units vest on 8/15/2025 and 118 restricted stock units vest on 8/15/2026.

160 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027.

38 restricted stock units vest on each of 2/3/2026 and 2/3/2027, and 39 restricted stock units vest on 2/3/2028.

311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028.

Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028.

/s/ Andrew Nick as Attorney-in-Fact for Amy E. Herr pursuant to Power of Attorney previously filed


Represents shares that have been withheld by the Issuer to satisfy income tax withholding and remittance obligations in connection with the vesting of restricted stock units.

These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024.


On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the achievement of a clinical milestone, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on August 15, 2025.

Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.53 to $448.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.21 to $450.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.42 to $451.39. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.48 to $452.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.49 to $453.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.50 to $454.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.58 to $455.55. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.65 to $456.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 11, 2024.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.94 to $455.77. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $456.64 to $457.51. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $457.76 to $458.65. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $459.20 to $460.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $460.60 to $461.44. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.

Represents shares held in trust, of which the Reporting Persons spouse is co-trustee. The Reporting Person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

By: Brett Budzinski, Attorney-in-Fact For: Pushkal Garg


Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Fully exercisable.

Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

Options to purchase 7,348 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027 and options to purchase 7,347 shares vest on 8/15/2026.

Options to purchase 9,563 shares vest on each of 11/1/2024, 11/1/2025, 11/1/2026 and 11/1/2027.

Options to purchase 12,973 shares vest on each of 2/1/2025 and 2/1/2027, and options to purchase 12,972 shares vest on each of 2/1/2026 and 2/1/2028.

Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

8,543 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027.

Options to purchase 17,265 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 17,266 shares vest on 8/15/2028.

Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028.

Options to purchase 30,147 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.

/s/ Andrew Nick, Attorney-in-Fact for Kim Kelderman pursuant to Power of Attorney previously filed.


Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Fully exercisable.

Options to purchase 876 shares vest on each of 8/15/2023, 8/15/2025 and 8/15/2026, and options to purchase 880 shares vest on 8/15/2024.

Options to purchase 982 shares vest on each of 4/3/2024, 4/3/2025, 4/3/2026 and 4/3/2027.

2,259 restricted stock units vest on 4/3/2026.

Options to purchase 4,076 shares vest on 8/15/2024 and 8/15/2026, and options to purchase 4,075 shares vest on 8/15/2025 and 8/15/2027.

49 restricted stock units vest on 8/15/2026.

1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027.

Options to purchase 3,372 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.

2,332 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.

Options to purchase 5,966 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 5,965 shares vest on 8/15/2028.


Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.

/s/ Andrew J. McCormick, as attorney-in-fact


On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the achievement of a clinical milestone, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on August 15, 2025.

Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.53 to $448.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.21 to $450.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.42 to $451.39. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.48 to $452.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.49 to $453.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.50 to $454.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.58 to $455.55. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.65 to $456.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

By: Brett Budzinski, Attorney-in-Fact For: Tolga Tanguler


Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

4,620 restricted stock units vest on 2/1/2025 and 2/1/2027, and 4,621 restricted stock units vest on 2/1/2026.

Options to purchase 3,976 shares vest on 2/1/2025 and 2/1/2027, and options to purchase 3,975 shares vest on 2/1/2026 and 2/1/2028.

Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

2,637 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 2,638 restricted stock units vest on 8/15/2027.

Options to purchase 5,330 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.

Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

3,207 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 3,208 restricted stock units vest on 8/15/2028.

Options to purchase 8,205 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 8,204 shares vest on 8/15/2028.

/s/ Andrew Nick as Attorney-in-Fact for Matthew McManus pursuant to Power of Attorney previously filed.


On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the achievement of a clinical milestone, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on August 15, 2025.

Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.53 to $448.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.21 to $450.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.42 to $451.39. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.48 to $452.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.49 to $453.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.50 to $454.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.58 to $455.55. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.65 to $456.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.

By: Brett Budzinski, Attorney-in-Fact For: Jeffrey V. Poulton


Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

Options to purchase 3,980 shares vest on each of 2/1/2023 and 2/1/2025, and options to purchase 3,976 shares vest on each of 2/1/2024 and 2/1/2026.

Options to purchase 7,400 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.

Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

Options to purchase 7,515 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2027, and 7,514 shares vest on 8/15/2026.

9,911 restricted stock units vest on 11/1/2025.

Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

2,623 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027.

Options to purchase 5,301 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.

Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

3,226 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.

Options to purchase 8,253 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 8,252 shares vest on 8/15/2028.

/s/ Andrew Nick as Attorney-in-Fact for William Geist pursuant to Power of Attorney previously filed


On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the achievement of a clinical milestone, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on August 15, 2025.

Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.53 to $448.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.21 to $450.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.42 to $451.39. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.48 to $452.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.49 to $453.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.50 to $454.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.58 to $455.55. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.65 to $456.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.

By: Brett Budzinski, Attorney-in-Fact For: Yvonne Greenstreet


By: Brett Budzinski, Attorney-in-Fact For: Kevin Fitzgerald


Common Stock

This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on November 12, 2024.

The shares of ALNY common stock were purchased by the Michael W. Bonney Revocable Trust, of which the reporting person is trustee.

The stock option was fully vested as of June 3, 2017.

By: Brett Budzinski, Attorney-in-Fact For: Michael W. Bonney


The reported price is a weighted average price. These shares of AXS Common Stock were sold in multiple transactions at prices ranging from $95.78 to $96.52 per share. Mr. Draper undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares of AXS Common Stock sold at each separate price within the range set forth in this footnote.

G. Christina Gray-Trefry, Attorney-in-Fact


/s/ Stephanie N. Berberich, Attorney-in-Fact


Represents an award of restricted stock units ("RSUs") that vests over a four-year period as follows: 25% of the RSUs shall vest on May 15, 2026 and 25% of the RSUs shall vest each annual anniversary thereafter, subject to the Reporting Person's continuous status as an employee or service provider through each vesting date.

Exempt transaction pursuant to Section 16b-3(e) - Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3. All of the shares reported as disposed of in this line item were relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of any of the shares reported in this line item for any reason other than to cover required taxes.

Includes 2,500 shares acquired under the Issuer's employee stock purchase plan on August 15, 2025.

/s/ Tyler Gee, Attorney-in-Fact for Jason C. Stephen


/s/Tyler Gee, Attorney-in-Fact for Nicholas Woodman


/s/ Tyler Gee, Attorney-in-Fact for Brian McGee


Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date.

By: Justin Hunter For: Benjamin R. Wheeler


Marc J. Desoer and Barbara J. Desoer 1998 Trust dated September 7, 1998


/s/ Tyler Gee, Attorney-in-Fact for Dean Jahnke


Stock Option (Right to buy Class B Common Stock)

Class B Common Stock

Class A Common Stock

Class A Common Stock

Class A Common Stock

Class A Common Stock

Class A Common Stock

Class A Common Stock

Class A Common Stock

Class A Common Stock

Each share of Class B common stock held by the Issuer's executive officers, directors and their respective affiliates will convert automatically into one share of Class A common stock upon any transfer, except for certain permitted transfers.

Following the sales reported in this line item, Mr. Goel holds 2,362,194 shares of Class A Common Stock and Class B Common Stock, which figure does not reflect vested but unexercised options, unvested options, or unvested restricted stock units, each as of the date of filing.  The option award under which these shares were exercised expires on July 7, 2026.

The sales reported in this line item were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 2, 2025.

These securities were transferred by the Reporting Person to The Goel Family Trust, of which the Reporting Person and his spouse are beneficiaries, and were sold by the Goel Family Trust as reported herein.

Represents the weighted average sale price. The lowest price at which shares were sold was $8.31 and the highest price at which shares were sold was $8.515. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

The options are fully vested.

These securities are held by the Reporting Person, as custodian for the benefit of his children under the California Uniform Transfers to Minors Act.

These securities are held by The Goel Heritage Trust, of which the Reporting Person's children are beneficiaries. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

These securities are held by The Goel Family Gift Trust, of which family members and certain other individuals are beneficiaries. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

These securities are held by a trust for the benefit of the Reporting Person's child. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

These securities are held by The Goel Family Trust, of which the Reporting Person and his spouse are beneficiaries.


/s/ Paul Richards, as attorney-in-fact for Brian Mitts


/s/ Tyler Gee, Attorney-in-Fact for Charles Lafrades


Common Stock, par value $0.001 per share

Common Stock, par value $.001 per share

Common Stock, par value $.001 per share

Held by Moriah Stone Global L.P. of which Mr. Adamczyk is controlling partner.

Options were issued in exchange for services rendered as an officer and director of the company.

3,500,000 shares of Common Stock underlie these options and were not affected by the transactions reported in this Form 4.

500,000 of Mr. Adamczyk's options are held in the name of Adamczyk Family 2021 LLC, a family limited liability company which he controls. None of these options were exercised.


Common Stock

Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.

With tandem dividend equivalent rights and tax withholding rights.

Includes 141 dividend equivalent units that had accrued on the restricted stock units.

The restricted stock units were granted on August 15, 2024 and vest in three equal installments on the first, second and third anniversaries of the grant date, subject to Ms. Radkoski's continued employment with the Company on the applicable vesting date. The first installment (including the related dividend equivalent units) vested on August 15, 2025.


Common Stock

Common Stock

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.115 to $7.170, inclusive. The Reporting Person undertakes to provide to Armada Hoffler Properties, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.

Represents common units of limited partnership interest ("Common Units") in Armada Hoffler, L.P. (the "Operating Partnership"), the operating partnership of the Company, and of which the Company is the general partner. All Common Units reflected in this report were issued more than one year prior to the date hereof and, therefore, may be tendered for redemption by the holder.

Each Common Unit is redeemable for cash equal to the then-current market value of one share of the Company's common stock or, at the election of the Company, one share of the Company's common stock. Common Units have no expiration date.

Represents Time-Based LTIP Units in the Operating Partnership ("Time-Based LTIP Units"). Under the agreement of limited partnership of the Operating Partnership (the "OP Agreement") and subject to conditions set forth in the OP Agreement, following the date on which the Time-Based LTIP Units vest, Time-Based LTIP Units are convertible into Common Units at the holder's option. Under the award agreement pursuant to which the Time-Based LTIP Units were granted to the Reporting Person, except in connection with a Change of Control (as defined in the OP Agreement), the Time-Based LTIP Units may not be converted to Common Units until two years following the date of grant. Time-Based LTIP Units have no expiration date.

/s/ Matthew T. Barnes-Smith, Attorney-in-Fact for Eric E. Apperson


Class A Common Stock

Class A Common Stock

Class A Common Stock

The sales reported on this line represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs"). The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction.

The price reported in Column 4 is a weighted average price. These shares were sold as part of a block trade for multiple security holders of the Issuer at prices ranging from $8.30 to $8.515, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade.

Each RSU represents a right to receive one share of the Issuer's Class A Common Stock at the time of vesting for no consideration.

The RSUs vest as to 1/4 of the total shares on August 15, 2024, and 1/16th of the total shares will vest quarterly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

RSUs do not expire; they either vest or are canceled prior to the vesting date.

The RSUs vest as to 1/16 of the total shares quarterly beginning on May 15, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

The RSUs vest as to 1/16th of the total shares on May 15, 2025, and 1/16th of the total shares will vest quarterly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.


Common Stock (Long-Term Incentive Performance-Based RSUs)

These shares have been withheld and not issued to the Reporting Person in order to satisfy certain tax witholding obligations incident to the vesting on August 15, 2025 of one-third of the restricted stock units previously granted to the Reporting Person on  August 15, 2024 pursuant to the Deckers Outdoor Corporation 2015 Stock Incentive Plan.

The Time-Based Restricted Stock Units (the Time-Based RSUs) were granted pursuant to the Issuer's 2024 Stock Incentive Plan. The Time-Based RSUs vest as to 33.33% of the underlying shares on 8/15/2026, 33.33% on 8/15/2027, and 33.34% on 8/15/2028, subject to the satisfaction of continuous service requirements. At the time that continuous service requirements cease to be met, no further vesting will occur and the remaining Time-Based RSUs will not be earned. The Time-Based RSUs will be settled in the Issuer's common stock upon satisfaction of the vesting conditions.

Refer to Exhibit 99 for additional information.

The amounts listed are the maximum number of LTIP Performance RSUs that may vest.

/s/ Lisa Bereda for Robin Spring-Green as Attorney in Fact


Shares withheld to cover tax liability associated with the vesting of restricted stock units.


These shares have been withheld and not issued to the Reporting Person in order to satisfy certain tax witholding obligations incident to the vesting on August 15, 2025 of one-third of the restricted stock units previously granted to the Reporting Person on  August 15, 2022, August 15, 2023 and August 15, 2024 pursuant to the Deckers Outdoor Corporation 2015 Stock Incentive Plan.

/s/ Lisa Bereda for Marco Ellerker as Attorney in Fact


Represents shares of common stock of Sanara MedTech Inc. (the "Issuer") withheld by the Issuer to satisfy tax withholding obligations in connection with the accelerated vesting of 9,543 shares of restricted stock previously granted to the reporting person. No shares were issued or sold in this transaction. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market.


Alico, Inc., Common Stock, Par Value $1.00

The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $32.18  to $33.085, inclusive.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

As previously reported, the Reporting Person was the Managing Member of Rinyami, LLC, which previously held 128,571 shares.  That entity was dissolved in April 2020, after which time the Reporting Person directly held 38,571 shares of those shares.  The amount reported reflects those shares, and the previously reported 27,867 shares issued under the Stock Incentive Plan of 2015, as adjusted for this transaction.

Montac Trust, a trust of which Mr. Slack is a beneficiary, holds 1,820 shares of the Company's Common Stock.  Mr. Slack disclaims beneficial ownership of the shares held by such trust except to the extent of his pecuniary interest therein. The two family trusts (the "Family Trusts") previously reported were dissolved.

/s/ Brad Heine, Attorney-in-Fact for Henry R. Slack


1.These shares have been withheld and not issued to the Reporting Person in order to satisfy certain tax witholding obligations incident to the vesting on August 15, 2025 of one-third of the restricted stock units previously granted to the Reporting Person on  August 15, 2022, August 15, 2023 and August 15, 2024 pursuant to the Deckers Outdoor Corporation 2015 Stock Incentive Plan.

/s/ Lisa Bereda for Steven Fasching as Attorney in Fact


Common Stock, $.01 Par Value

Common Stock, $.01 Par Value

Common Stock, $.01 Par Value

Common Stock, $.01 Par Value

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 8, 2025.

Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan.

This option was granted on February 27, 2019.  The option vested in three equal annual installments on the first, second and third anniversaries of the grant date.

This option was granted on February 28, 2018.  The option vested in three equal annual installments on the first, second and third anniversaries of the grant date.

EVP, Chief Administrative Officer and General Counsel


Shares of Plexus Corp. common stock held in the Plexus Corp. 401(k) Retirement Plan as of the last report from the Plan's trustee.

Shares of Plexus Corp. common stock were given as a bona fide gift.

/s/ Oliver K. Mihm, by Kate A. Gitter, Attorney-in-Fact


Common Stock (Long-Term Incentive Performance Based RSUs)

These shares have been withheld and not issued to the Reporting Person in order to satisfy certain tax witholding obligations incident to the vesting on August 15, 2025 of one-third of the restricted stock units previously granted to the Reporting Person on  August 15, 2023 and August 15, 2024 pursuant to the Deckers Outdoor Corporation 2015 Stock Incentive Plan.

The Time-Based Restricted Stock Units (the Time-Based RSUs) were granted pursuant to the Issuer's 2024 Stock Incentive Plan. The Time-Based RSUs vest as to 33.33% of the underlying shares on 8/15/2026, 33.33% on 8/15/2027, and 33.34% on 8/15/2028, subject to the satisfaction of continuous service requirements. At the time that continuous service requirements cease to be met, no further vesting will occur and the remaining Time-Based RSUs will not be earned. The Time-Based RSUs will be settled in the Issuer's common stock upon satisfaction of the vesting conditions.

Refer to Exhibit 99 for additional information.

The amounts listed are the maximum number of LTIP Performance RSUs that may vest.

/s/Lisa Bereda for Anne Spangenberg as Attorney in Fact


Owned jointly with spouse.


Shares withheld to satisfy tax obligations arising out of vesting of  Restricted Stock Award.

/s/ Ahalya Hildreth, Attorney-in-Fact for Paul Scannell


These shares have been withheld and not issued to the Reporting Person in order to satisfy certain tax witholding obligations incident to the vesting on August 15, 2025 of one-third of the restricted stock units previously granted to the Reporting Person on  August 15, 2022, August 15, 2023 and August 15, 2024 pursuant to the Deckers Outdoor Corporation 2015 Stock Incentive Plan.

/s/ Lisa Bereda for Angela Ogbechie as Attorney in Fact


Common Stock, par value $.01  per share

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/07/2024.

Represents the weighted average sale price. The highest price at which shares were sold was $232.25 and the lowest price at which shares were sold was $231.29.

Represents the weighted average sale price. The highest price at which shares were sold was $233.26 and the lowest price at which shares were sold was $232.35.

Represents the weighted average sale price. The highest price at which shares were sold was $233.80 and the lowest price at which shares were sold was $233.63.

Converts into Common Stock on a one-for-one basis.

This award vests based upon the following vesting schedule: 39,466 shares on each of November 15, 2022 and February 15, 2023; 9,659 shares on each of May 15, 2023, August 15, 2023, November 15, 2023, and February 15, 2024; 13,753 shares on each of May 15, 2024, August 15, 2024, and November 15, 2024; 13,752 shares on February 15, 2025; 11,960 shares on May 15, 2025; 11,959 shares on each of August 15, 2025, November 15, 2025, and February 15, 2026; 9,353 shares on May 15, 2026; 9,352 shares on each of August 15, 2026, November 15, 2026, and February 15, 2027; 7,218 shares on each of May 15, 2027, August 15, 2027, and November 15, 2027; and 7,217 shares on February 15, 2028.

The reporting person undertakes to provide, upon request by the staff of the SEC, the issuer, or a security holder of the issuer, full information regarding the number of shares transacted at each price, with respect to all transactions reported on this Form 4.

/s/ by Mark F. Hoffman as attorney-in-fact for Douglas J. Herrington, CEO Worldwide Amazon Stores


These shares have been withheld and not issued to the Reporting Person in order to satisfy certain tax witholding obligations incident to the vesting on August 15, 2025 of one-third of the restricted stock units previously granted to the Reporting Person on  August 15, 2022 and August 15, 2023 pursuant to the Deckers Outdoor Corporation 2015 Stock Incentive Plan.

Reflects forfeitures of restricted stock units and long-term performance based awards granted on August 15, 2023 in connection with Mr. Powers' retirement.

/s/ Lisa Bereda for David Powers as Attorney in Fact


Represents the number of shares of common stock withheld by the issuer to cover the reporting person's tax liability associated with the vesting of shares underlying certain restricted stock units on August 15, 2025 and does not represent a sale by the reporting person.

Represents the number of shares of common stock withheld by the issuer to cover the reporting person's tax liability associated with the vesting of shares underlying certain performance-based restricted stock units on August 15, 2025 and does not represent a sale by the reporting person.


Common Stock

The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.17 to $37.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The option is fully vested and exercisable.

/s/ Colleen Tupper as Attorney-in-Fact for Gino Santini


The Time-Based Restricted Stock Units (the Time-Based RSUs) were granted pursuant to the Issuer's 2024 Stock Incentive Plan. The Time-Based RSUs vest as to 33.33% of the underlying shares on 8/15/2026, 33.33% on 8/15/2027, and 33.34% on 8/15/2028, subject to the satisfaction of continuous service requirements. At the time that continuous service requirements cease to be met, no further vesting will occur and the remaining Time-Based RSUs will not be earned. The Time-Based RSUs will be settled in the Issuer's common stock upon satisfaction of the vesting conditions.

Refer to Exhibit 99 for additional information.

The amounts listed are the maximum number of LTIP Performance RSUs that may vest.

/s/ Lisa Bereda for Stefano Caroti as Attorney in Fact


/s/ Jonathan Gelfand, Attorney-in-Fact for Bradley Ramberg


/s/ Lisa Bereda for Thomas Garcia as Attorney in Fact


Includes: (i) 13,515 shares granted under a Performance Unit Award Agreement that vest on 12/31/2025 through 12/31/2029; (ii) 8,144 shares granted under a Performance Unit Award Agreement that vest on 12/31/2025 through 12/31/2028; (iii) 5,259 shares granted under a Performance Unit Award Agreement that vest on 12/31/2025 through 12/31/2027; (iv) 4,182 shares granted under a Performance Unit Award Agreement that vest on 12/31/2025 through 12/31/2026; and (v) 2,400 shares granted under a Performance Unit Award Agreement that vest on 12/31/2025.

/s/ James J. Hinnendael, attorney-in-fact


Transaction effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024.


/s/ Jeannine J. Lane, as Attorney-in-Fact for Michael Carlet